값Q4, 24TTM판매비·일반관리비——연구개발——영업 이익——비영업 수익, 합계——이자비용(자본화한 이자 차감 후)——이자비용을 제외한 비영업 수익——비정상 수입/지출——세전소득——지분법 손익——세금——비지배 지분——세후 기타 수익/비용——중단된 사업 부문 제외 순이익——중단된 사업——순이익——희석보정——우선배당——보통주주에게 귀속되는 희석 순이익——주당 순이익(기본 EPS)——희석 주당 순이익 (희석 EPS)——평균 발행주식수——희석주식수——EBITDA——EBIT——매출원가——기타 매출원가——감가상각 및 무형자산 상각 (현금흐름)——
Immuron Limited - American Depositary Shares
Immuron is a biotechnology company based in Melbourne, Australia. In 2008, the company changed its name to Immuron Limited, having previously operated as Anadis Limited.
Immuron is focused on antigen-primed and dairy-derived health products. Its proprietary technologies allow for rapid development of polyclonal antibody and other proteins-based solutions for a range of diseases. The company specialises in nutraceutical, pharmaceutical and therapeutic technology products for conditions such as oral and GI mucositis, avian influenza, E. coli travellers' diarrhoea and Anthrax containment.
In 2005, Anadis signed an agreement with Quebec's Baralex Inc. and Valeo Pharma Inc. for the distribution of Travelan, a product made by Anadis for the Canadian market.